Association of Some Surrogate Inflammatory Markers and Non - invasive Measures of Liver Fibrosis among Patients with HIV Infection
Archives of Medical Laboratory Sciences,
Vol. 10 (2024),
28 February 2024
,
Page 1-10 (e1)
https://doi.org/10.22037/amls.v10.41783
Abstract
Background and Aim: HIV is associated with inflammation and liver damage. Assay of inflammatory markers and liver biopsy are expensive for resource - poor countries to use routinely, necessitating the use of non - invasive markers. This study seeks to examine the association of some surrogate markers of inflammation with some non-invasive markers of fibrosis among patients with HIV infection in Benin City, Nigeria.
Methods: Venous blood was collected from all participants. The study was carried out in the University of Benin Teaching Hospital, Benin City, Nigeria. Surrogate inflammatory markers {such as neutrophil / lymphocyte ratio (NLR), platelet / lymphocyte ratio (PLR), mean platelet volume (MPV) and systemic immune - inflammatory index (SII)}, non - invasive markers of fibrosis {such as fibrosis index based on four factors (FIB-4), aspartate aminotransferase to platelet ratio index (APRI) and fibrosis - cirrhosis index (FCI)} and CD4 counts were evaluated in 125 patients with HIV infection {44 Highly Active Antiretroviral Therapy (HAART) - naïve and 81 on HAART)} and 48 non -HIV individuals using standard techniques.
Results: The prevalence of liver fibrosis among patients with HIV infection on HAART was 2.47%, 6.17% and 2.47% using APRI, FIB-4 and FCI respectively whereas only FIB-4 (6.82%) and FCI (2.27%) revealed liver fibrosis in HAART - naïve patients. NLR, SII and PLR were significantly higher in HAART - naïve patients than those on HAART. PLR was also significantly higher in HAART-naïve HIV patients compared to non-HIV patients (p < 0.01). FIB-4 was significantly higher in patients with HIV infection on HAART (1.54 ± 0.30) than in non-HIV individuals (0.54 ± 0.06) (p<0.05). PLR, MPV and CD4 count had a significant correlation with some of the markers of fibrosis in patients with HIV infection in the different study groups.
Conclusion: Liver fibrosis was detected more with FIB-4, and PLR was the only inflammatory marker that significantly correlated with all markers of liver damage among patients with HIV infection on HAART.
*Corresponding Author: Richard Omoregie; Email: richard.omoregie@ubth.org; ORCID ID: 0000-0002-8601-159X
Please cite this article as: Aikpitanyi-Iduitua GA, Lawrence Idemudia N, Aikpitanyi-Iduitua RO, Omoregie R. Association of Some Surrogate Inflammatory Markers and Non - invasive Measures of Liver Fibrosis among Patients with HIV Infection. Arch Med Lab Sci. 2024;10:1-10 (e1). https://doi.org/10.22037/amls.v9.41783
How to Cite
References
1. UNAIDS Global HIV & AIDS Statistics—2020 Fact Sheet. [(accessed on 17 October 2021)]. Available online: https://www.unaids.org/en/resources/fact-sheet.
2. Joshi D, O’Grady J, Dieterich D, Gazzard B, Agarwal K. Increasing burden of liver disease in patients with HIV infection. Lancet. 2011; 377: 1198–1209. doi: 10.1016/S0140-6736(10)62001-6.
3. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): A multicohort collaboration. Lancet. 2014; 384: 241–248. doi: 10.1016/S0140-6736(14)60604-
4. Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 2006; 166: 1632–1641. doi: 10.1001/archinte.166.15.1632.
5. Neukam K, Mira JA, Collado A, Rivero-Juárez A, Monje-Agudo P, Ruiz-Morales J, et al. Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort. PLoS One 2016; 11: e0148104.doi:10.1371/journal.pone.0148104
6. Eyawo O, Franco-Villalobos C, Hull MW, Nohpal A, Samji H, Sereda P, et al. Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012. BMC Infect Dis 2017; 17: 174. doi: 10.1186/s12879-017-2254-7.
7. Bataller, R, Brenner, DA. Liver fibrosis. J Clin Invest 2005; 115(2): 209–218. https://doi.org/10.1172/JCI24282
8. Bruno R, Galastri S, Sacchi P, Cima S, Caligiuri A, DeFranco R, et al. gp120 modulates the biology of human hepatic stellate cells: A link between HIV infection and liver fibrogenesis. Gut 2010; 59: 513-520.
9. Glassner A, Eisenhardt M, Kokordelis P, Krämer B, Wolter F, Nischalke HD, et al. Impaired CD4+ T cell stimulation of NK cell anti-fibrotic activity may contribute to accelerated liver fibrosis progression in HIV/HCV patients. J Hepatol 2013; 59: 427-433.
10. Maagaard A, Holberg-Peterson M, Løvgården G, Holm M, Pettersen FO, Kvale D. Distinct mechanisms for mitochondrial DNA loss in T and B lymphocytes from HIV-infected patients exposed to nucleoside reversetranscriptase inhibitors and those naive to antiretroviral treatment. J Infect Dis 2008; 198:1474-1481.
11. Morse CG, Voss JG, Rakocevic G, McLaughlin M, Vinton CL, Huber C, et al. HIV infection and antiretroviral therapy have divergent effects on mitochondria in adipose tissue. J Infect Dis 2012; 205: 1778-1787.
12. Pérez-Matute P, Pérez-Martínez L, Blanco JR, Oteo JA. Role of mitochondria in HIV infection and associated metabolic disorders: Focus on nonalcoholic fatty liver disease and lipodystrophy syndrome. Oxid Med Cell Longev 2013;2013:493413.
13. Riley JL, Montaner LJ. Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir. J Infect Dis 2017; 215(3): 160–171. https://doi.org/10.1093/infdis/jix002
14. Rock KL, Kono H. The inflammatory response to cell death. Ann. Rev. Path. 2008; 3: 99–126. https://doi.org/10.1146/annurev.pathmechdis.3.121806.151456
15. Marchionatti A, Parisi MM. Anemia and thrombocytopenia in people living with HIV/AIDS: a narrative literature review. Int Health, 2021; 13(2): 98–109. https://doi.org/10.1093/inthealth/ihaa036
16. Gunduz S, Mutlu H, Tural D, Yıldız Ö, Uysal M, Coskun HS, et al. Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer. Asia Pac J Clin Oncol 2015; 11:288–292. doi: 10.1111/ajco. 12358.
17. Liu J, Du J, Fan J, Liu K, Zhang B, Wang S, et al. The Neutrophil-to-Lymphocyte Ratio Correlates with Age in Patients with Papillary Thyroid Carcinoma. ORL J. Otorhinolaryngol Relat Spec 2015; 77: 109–116.
18. Oylumlu M, Yıldız A, Oylumlu M, Yüksel M, Polat N, Bilik MZ, et al. Platelet-to-lymphocyte ratio is a predictor of in-hospital mortality patients with acute coronary syndrome. Anatol J Cardiol 2015; 15: 277–283.
19. Idemudıa NL, Ogefere HO, Omoregie R. Use of Some Surrogate Markers of Inflammation as Predictor of Malaria Severity. J Microbol Infect Dis. 2021; 11(04): 201-208.
20. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010; 8: 877–883.
21. Singal G, Thomassen LV, Gretch DR, Shuhart MC. Use of the AST to platelet ratio index in HCV/HIV co-infected Patients. Aliment Pharmacol Ther 2011; 33: 566-77.
22. Kliemann DA, Wolff FH, Tovo CV, Alencastro PR, Ikeda MLR, Brandão ABM, et al. Biochemical non-invasive assessment of liver fibrosis cannot replace biopsy in HIV-HCV coinfected patients. Ann Hepat 2016; 15(1): 27-32.
23. So-Armah KA, Tate JP, Chang CH, Butt AA, Gerschenson M, Gibert CL, et al. Do biomarkers of inflammation, monocyte activation, and altered coagulation explain excess mortality between HIV infected and uninfected people? J Acquir Immune Defic Syndr 2016; 72: 206–13.
24. Márquez M, Romero-Cores P, Montes-Oca M, Martín-Aspas A, Soto-Cárdenas MJ, Guerrero F, et al. Immune activation response in chronic HIV-infected patients: influence of Hepatitis C virus coinfection. PLoS One 2015; 10: e0119568
25. Basu A, Ghosh K, Banerjee K. Bone marrow involvement in HIV infection: light, electron and immuno electron microscopic studies. Indian J Hematol & Blood Transf 1999; 17(4): 76-86.
26. Mohamad WMW, Rahman WSWA, Al-Salih SAA, Hussin CMC. Immunological and Haematological Changes in HIV Infection. In (Ed.), Trends in Basic and Therapeutic Options in HIV Infection - Towards a Functional Cure. IntechOpen. 2015. https://doi.org/10.5772/61259
27. Hileman CO, Funderburg NT. Inflammation, immune activation, and antiretroviral therapy in HIV. Curr HIV/AIDS Rep 2017; 14(3): 93 – 100
28. Lohse N, Hanson AB, Pederson G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection Denmark, 1995 – 2005. Ann. Intern. Med. 2007; 146: 87 – 95.
29. Olawumi HO, Olatunji PO, Salami AK, Odeigah L, Iseniyi JO. Effect of highly active antiretroviral therapy on CD4 count and weight in AIDS patients seen at the UITH, Ilorin. Nig J. Clin Pract. 2008; 11(4): 312 – 315
30. Blackard JT, Welge JA, Taylor LE, Mayer KH, Klein RS, Celentano DD, et al. HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women. Clin Infect Dis 2011; 52(5): 674–680. https://doi.org/10.1093/cid/ciq199
31. Madzime M, Rossouw TM, Theron AJ, Anderson R, Steel HC. Interactions of HIV and antiretroviral therapy with neutrophils and platelets. Front Immunol 2021; 12: 634386. doi: 10.3389/fimmu.2021.634386
32. Huang D, Lin T, Wang S, Cheng L, Xie L, Lu Y, et al. The liver fibrosis index is superior to the APRI and FIB-4 for predicting liver fibrosis in chronic hepatitis B patients in China. BMC Infectious Diseases 2019; 19:878 https://doi.org/10.1186/s12879-019-4459-4
33. Koyama Y, Brenner DA. Liver inflammation and fibrosis. J. Clin. Invest. 2017; 127(1): 55 – 64
34. Senturk M, Azgin I, Ovet G, Alatas N, Agirgol B, Yilmaz E. The role of mean platelet volume and neutrophil-to-lymphocyte ratio in peritonsillar abscesses. Braz. J. Otorhinolaryngol. 82: 662-667.
35. Hamzeh-Cognasse H, Damien P, Chabert A, Pozzetto B, Cognasse F, Garraud O. Platelet and infections-complex interactions with bacteria. Front. Immunol 2015; 6: doi: 10.3389/fimmu.2015.00082
36. Aslam R, Speck ER, Kim M, Crow AR, Bang KW, Nestle FP, et al. Platelet toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumour necrosis factor-alpha production in vivo. Blood 2006; 107: 637-641.
37. Semple JW, Aslam R, Kim M, Speck ER. Freedman J. Platelet-bound polysaccharide enhances Fc receptor-mediated phagocytosis of IgG opsonised platelets. Blood 2007; 109: 4803-4805.
38. Kapur R, Zufferey A, Boilard E. Semple WJ. Nouvelle Cuisine: Platelets Served with Inflammation. J. Immunol. 2015; 194: 5579-5587.
39. Boyraz I, Koc¸ B, Boyacı A, Tuto˘glu A, Sarman H, Ozkan H. Ratio of neutrophil/lymphocyte and platelet/lymphocyte in patient with ankylosing spondylitis that are treating with anti-TNF. Int. J. Clin. Exp. Med. 2014; 7: 2912-2915.
40. Kilonzo SB, Gunda DW, Kashasha F, Mpondo BC. Liver fibrosis and hepatitis B coinfection among ART-naïve HIV-infected patients at a tertiary level hospital in Northwestern Tanzania: a cross-sectional study. J Trop Med 2017; 6. https://doi.org/10.1155/2017/5629130
- Abstract Viewed: 159 times
- PDF Downloaded: 117 times